152 related articles for article (PubMed ID: 37708796)
21. Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
Krug M; Erlenkamp G; Sippl W; Schächtele C; Totzke F; Hilgeroth A
Bioorg Med Chem Lett; 2010 Dec; 20(23):6915-9. PubMed ID: 21035334
[TBL] [Abstract][Full Text] [Related]
22. Engineering a monomeric variant of macrophage colony-stimulating factor (M-CSF) that antagonizes the c-FMS receptor.
Zur Y; Rosenfeld L; Bakhman A; Ilic S; Hayun H; Shahar A; Akabayov B; Kosloff M; Levaot N; Papo N
Biochem J; 2017 Jul; 474(15):2601-2617. PubMed ID: 28655719
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
Lv P; Chen K; Zhu HL
Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
[TBL] [Abstract][Full Text] [Related]
24. Molecular Modeling Studies of
Ghosh S; Keretsu S; Cho SJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830393
[TBL] [Abstract][Full Text] [Related]
25. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
Damghani T; Moosavi F; Khoshneviszadeh M; Mortazavi M; Pirhadi S; Kayani Z; Saso L; Edraki N; Firuzi O
Sci Rep; 2021 Feb; 11(1):3644. PubMed ID: 33574356
[TBL] [Abstract][Full Text] [Related]
26. Quinoline as a privileged scaffold in cancer drug discovery.
Solomon VR; Lee H
Curr Med Chem; 2011; 18(10):1488-508. PubMed ID: 21428893
[TBL] [Abstract][Full Text] [Related]
27. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
Illig CR; Manthey CL; Meegalla SK; Wall MJ; Chen J; Wilson KJ; DesJarlais RL; Ballentine SK; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Donatelli RR; Yurkow E; Zhou Z; Player MR; Tomczuk BE
Bioorg Med Chem Lett; 2013 Dec; 23(23):6363-9. PubMed ID: 24138939
[TBL] [Abstract][Full Text] [Related]
29. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
30. Regulation by Gi2 proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3.
Corre I; Baumann H; Hermouet S
Oncogene; 1999 Nov; 18(46):6335-42. PubMed ID: 10597233
[TBL] [Abstract][Full Text] [Related]
31. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
[TBL] [Abstract][Full Text] [Related]
32. Scaffolding protein Gab2 mediates differentiation signaling downstream of Fms receptor tyrosine kinase.
Liu Y; Jenkins B; Shin JL; Rohrschneider LR
Mol Cell Biol; 2001 May; 21(9):3047-56. PubMed ID: 11287610
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Guo J; Marcotte PA; McCall JO; Dai Y; Pease LJ; Michaelides MR; Davidsen SK; Glaser KB
Mol Cancer Ther; 2006 Apr; 5(4):1007-13. PubMed ID: 16648572
[TBL] [Abstract][Full Text] [Related]
34. Novel FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Expert Opin Investig Drugs; 2003 Dec; 12(12):1951-62. PubMed ID: 14640939
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
Noonberg SB; Benz CC
Drugs; 2000 Apr; 59(4):753-67. PubMed ID: 10804033
[TBL] [Abstract][Full Text] [Related]
36. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease.
Patel S; Player MR
Curr Top Med Chem; 2009; 9(7):599-610. PubMed ID: 19689368
[TBL] [Abstract][Full Text] [Related]
37. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Taylor JR; Brownlow N; Domin J; Dibb NJ
Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
[TBL] [Abstract][Full Text] [Related]
38. Receptor tyrosine kinases: the main targets for new anticancer therapy.
Drevs J; Medinger M; Schmidt-Gersbach C; Weber R; Unger C
Curr Drug Targets; 2003 Feb; 4(2):113-21. PubMed ID: 12558064
[TBL] [Abstract][Full Text] [Related]
39. Recent Trends in Rationally Designed Molecules as Kinase Inhibitors.
Prasher P; Sharma M; Chan Y; Singh SK; Anand K; Dureja H; Jha NK; Gupta G; Zacconi F; Chellappan DK; Dua K
Curr Med Chem; 2023; 30(13):1529-1567. PubMed ID: 34766883
[TBL] [Abstract][Full Text] [Related]
40. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation.
Chihara T; Suzu S; Hassan R; Chutiwitoonchai N; Hiyoshi M; Motoyoshi K; Kimura F; Okada S
Cell Death Differ; 2010 Dec; 17(12):1917-27. PubMed ID: 20489731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
